CRSP
Crispr Therapeutics AG
54.00$
-5.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | -187.1% | – | – | – | – | – | – | – | – | – | |
| – | -0.5% | -1.4% | +0.2% | -2.2% | +2.2% | -2.2% | -1.8% | -4.6% | +27.7% | -23.7% | +99.1% | – | |
| – | -7.8% | +5.3% | +22.0% | -9.0% | +1.9% | -7.9% | -12.9% | -5.7% | +8.9% | -9.7% | +106.1% | – | |
| – | -488.1% | – | -95.0% | -484.7% | – | – | -130.1% | – | +107.5% | -168.1% | – | – | |
| – | -65.2% | -2.3% | -1.9% | -69.0% | +16.0% | -18.9% | -43.2% | -36.8% | +598.6% | -2.5% | +128.6% | – | |
| – | -167.1% | +20.1% | +29.8% | +27.3% | – | -118.7% | – | -270.4% | – | -1,204.2% | +13.6% | – | |
| – | – | – | – | – | – | – | – | +0.0% | – | – | – | – | |
| – | +2,402.5% | +685.7% | -100.2% | – | +75.1% | -37.3% | -78.7% | +13,042.9% | -60.8% | +408.5% | +1.2% | – | |
| – | -266.7% | – | -170.1% | – | – | -186.9% | – | – | -34.3% | +12.2% | -187.2% | – | |
| – | – | – | -188.3% | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.